There is accumulating evidence that LPS can activate Programmed Cell Death Ligand 1 (PD-L1) expression and improve immune escape in pancreatic cancer by activating the TLR4/MyD88/ NF-Kappa B pathway and the P13K/Akt/mTOR signaling pathway. The gene discussed is CD274; the disease is pancreatic neoplasm.